Here's Why Moderna May Dominate the Vaccine Market This Fall

Moderna (NASDAQ: MRNA) shares climbed more than 2% yesterday after the company took a big step toward handling one of the world's biggest coronavirus challenges: protecting populations against new variants.

The biotech company said its booster candidate targeting the original coronavirus and the omicron variant showed "superior" performance against omicron. Current vaccines are less efficacious against omicron than they are against the original virus and even other variants. And studies show protection against omicron wanes quickly, so Moderna's news could be a game changer. Let's take a closer look at where Moderna stands today -- and the company's prospects considering this new element.

There's been reason to be positive about Moderna ever since the company brought its vaccine to market. Moderna has reported billions of dollars in revenue and profit.

Source Fool.com